de Northern Trust ANI Pharmaceuticals ANIP Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 17.3 M | Comprar |
209,163
+24,311
| +13% | +USD 1.95 M | ﹤0.01% | 1885 |
|
|
2026
Q1 | USD 14.2 M | Comprar |
184,852
+8,038
| +5% | +USD 627 k | ﹤0.01% | 1879 |
|
|
2025
Q4 | USD 14 M | Vender |
176,814
-11,785
| -6% | -USD 1.02 M | ﹤0.01% | 1902 |
|
|
2025
Q3 | USD 17.3 M | Vender |
188,599
-874
| -0.5% | -USD 71.3 k | ﹤0.01% | 1790 |
|
|
2025
Q2 | USD 12.4 M | Vender |
189,473
-27,389
| -13% | -USD 1.78 M | ﹤0.01% | 1940 |
|
|
2025
Q1 | USD 14.5 M | Comprar |
216,862
+12,517
| +6% | +USD 748 k | ﹤0.01% | 1821 |
|
|
2024
Q4 | USD 11.3 M | Comprar |
204,345
+16,820
| +9% | +USD 966 k | ﹤0.01% | 2056 |
|
|
2024
Q3 | USD 11.2 M | Comprar |
187,525
+19,780
| +12% | +USD 1.21 M | ﹤0.01% | 2005 |
|
|
2024
Q2 | USD 10.7 M | Comprar |
167,745
+4,399
| +3% | +USD 286 k | ﹤0.01% | 1958 |
|
|
2024
Q1 | USD 11.3 M | Vender |
163,346
-3,756
| -2% | -USD 227 k | ﹤0.01% | 1962 |
|
|
2023
Q4 | USD 9.21 M | Vender |
167,102
-3,083
| -2% | -USD 170 k | ﹤0.01% | 2128 |
|
|
2023
Q3 | USD 9.9 M | Comprar |
170,185
+15,633
| +10% | +USD 902 k | ﹤0.01% | 2016 |
|
|
2023
Q2 | USD 8.32 M | Comprar |
154,552
+14,710
| +11% | +USD 652 k | ﹤0.01% | 2195 |
|
|
2023
Q1 | USD 5.55 M | Vender |
139,842
-1,672
| -1% | -USD 70.5 k | ﹤0.01% | 2397 |
|
|
2022
Q4 | USD 5.69 M | Comprar |
141,514
+4,735
| +3% | +USD 178 k | ﹤0.01% | 2406 |
|
|
2022
Q3 | USD 4.4 M | Comprar |
136,779
+845
| +0.6% | +USD 28.9 k | ﹤0.01% | 2567 |
|
|
2022
Q2 | USD 4.03 M | Comprar |
135,934
+11,333
| +9% | +USD 327 k | ﹤0.01% | 2642 |
|
|
2022
Q1 | USD 3.5 M | Vender |
124,601
-1,158
| -0.9% | -USD 43.2 k | ﹤0.01% | 2787 |
|
|
2021
Q4 | USD 5.8 M | Comprar |
125,759
+7,374
| +6% | +USD 317 k | ﹤0.01% | 2599 |
|
|
2021
Q3 | USD 3.88 M | Vender |
118,385
-196
| -0.2% | -USD 6.09 k | ﹤0.01% | 2893 |
|
|
2021
Q2 | USD 4.16 M | Comprar |
118,581
+1,528
| +1% | +USD 52 k | ﹤0.01% | 2961 |
|
|
2021
Q1 | USD 4.23 M | Vender |
117,053
-7,639
| -6% | -USD 239 k | ﹤0.01% | 2855 |
|
|
2020
Q4 | USD 3.62 M | Comprar |
124,692
+960
| +0.8% | +USD 27.5 k | ﹤0.01% | 2862 |
|
|
2020
Q3 | USD 3.49 M | Vender |
123,732
-4,371
| -3% | -USD 130 k | ﹤0.01% | 2752 |
|
|
2020
Q2 | USD 4.14 M | Vender |
128,103
-3,294
| -3% | -USD 118 k | ﹤0.01% | 2630 |
|
|
2020
Q1 | USD 5.35 M | Comprar |
131,397
+2,790
| +2% | +USD 148 k | ﹤0.01% | 2269 |
|
|
2019
Q4 | USD 7.93 M | Vender |
128,607
-4,510
| -3% | -USD 299 k | ﹤0.01% | 2326 |
|
|
2019
Q3 | USD 9.7 M | Comprar |
133,117
+14,076
| +12% | +USD 1.05 M | ﹤0.01% | 2164 |
|
|
2019
Q2 | USD 9.8 M | Comprar |
119,041
+2,404
| +2% | +USD 171 k | ﹤0.01% | 2168 |
|
|
2019
Q1 | USD 8.23 M | Vender |
116,637
-526
| -0.4% | -USD 30.9 k | ﹤0.01% | 2274 |
|
|
2018
Q4 | USD 5.27 M | Vender |
117,163
-928
| -0.8% | -USD 48.6 k | ﹤0.01% | 2468 |
|
|
2018
Q3 | USD 6.68 M | Comprar |
118,091
+1,285
| +1% | +USD 78.6 k | ﹤0.01% | 2514 |
|
|
2018
Q2 | USD 7.8 M | Comprar |
116,806
+4,710
| +4% | +USD 294 k | ﹤0.01% | 2430 |
|
|
2018
Q1 | USD 6.53 M | Vender |
112,096
-1,505
| -1% | -USD 95.5 k | ﹤0.01% | 2429 |
|
|
2017
Q4 | USD 7.32 M | Vender |
113,601
-43
| -0% | -USD 2.68 k | ﹤0.01% | 2378 |
|
|
2017
Q3 | USD 5.96 M | Comprar |
113,644
+739
| +0.7% | +USD 35.2 k | ﹤0.01% | 2522 |
|
|
2017
Q2 | USD 5.28 M | Comprar |
112,905
+5,599
| +5% | +USD 270 k | ﹤0.01% | 2601 |
|
|
2017
Q1 | USD 5.31 M | Comprar |
107,306
+4,141
| +4% | +USD 232 k | ﹤0.01% | 2529 |
|
|
2016
Q4 | USD 6.25 M | Comprar |
103,165
+1,884
| +2% | +USD 115 k | ﹤0.01% | 2402 |
|
|
2016
Q3 | USD 6.72 M | Comprar |
101,281
+1,681
| +2% | +USD 105 k | ﹤0.01% | 2331 |
|
|
2016
Q2 | USD 5.56 M | Comprar |
99,600
+451
| +0.5% | +USD 21.9 k | ﹤0.01% | 2386 |
|
|
2016
Q1 | USD 3.34 M | Comprar |
99,149
+924
| +0.9% | +USD 31.3 k | ﹤0.01% | 2671 |
|
|
2015
Q4 | USD 4.43 M | Comprar |
98,225
+7,206
| +8% | +USD 310 k | ﹤0.01% | 2531 |
|
|
2015
Q3 | USD 3.6 M | Comprar |
91,019
+10,644
| +13% | +USD 606 k | ﹤0.01% | 2667 |
|
|
2015
Q2 | USD 4.99 M | Comprar |
80,375
+5,140
| +7% | +USD 306 k | ﹤0.01% | 2518 |
|
|
2015
Q1 | USD 4.71 M | Comprar |
75,235
+1,911
| +3% | +USD 116 k | ﹤0.01% | 2540 |
|
|
2014
Q4 | USD 4.14 M | Vender |
73,324
-1,564
| -2% | -USD 69 k | ﹤0.01% | 2632 |
|
|
2014
Q3 | USD 2.12 M | Comprar |
74,888
+56,738
| +313% | +USD 1.7 M | ﹤0.01% | 3063 |
|
|
2014
Q2 | USD 625 k | Comprar |
18,150
+7,334
| +68% | +USD 230 k | ﹤0.01% | 3540 |
|
|
2014
Q1 | USD 339 k | Comprar |
10,816
+749
| +7% | +USD 19.9 k | ﹤0.01% | 3650 |
|
|
2013
Q4 | USD 202 k | Comprar |
+10,067
| Nuevas | +USD 131 k | ﹤0.01% | 3715 |
|
|
2013
Q3 | – | Vender |
-6,352
| Cerradas | -USD 38 k | – | 4078 |
|
|
2013
Q2 | USD 38 k | Comprar |
+6,352
| Nuevas | +USD 44.5 k | ﹤0.01% | 3957 |
|
Otros fondos que tienen ANIP en su cartera
Posición de Northern Trust en ANIP: resumen de T2 2026
Northern Trust aumentó su participación en ANI Pharmaceuticals (ANIP) en 13% durante T2 2026, al comprar aproximadamente USD 1.95 M y elevar la posición a 209,163 acciones con un valor de USD 17.3 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #1885.
Northern Trust reportó por primera vez una posición en ANIP en T2 2013 y la ha mantenido durante 52 trimestres desde entonces. Al cierre de T2 2026, 307 fondos que sigue Wall St. Rank mantienen una posición en ANIP.
- Al cierre de T2 2026, Northern Trust tenía 209,163 acciones de ANI Pharmaceuticals con un valor de USD 17.3 M.
- Northern Trust compró 24,311 acciones de ANI Pharmaceuticals en T2 2026, por un monto estimado de USD 1.95 M.
- ANI Pharmaceuticals representó ﹤0.01% de la cartera de Northern Trust en T2 2026 y fue su posición número 1885.
- Northern Trust reportó por primera vez una posición en ANI Pharmaceuticals en T2 2013 y la ha mantenido durante 52 trimestres desde entonces.
- Al cierre de T2 2026, 307 fondos que sigue Wall St. Rank tenían ANI Pharmaceuticals en cartera.
Según el Informe 13F de Northern Trust correspondiente a T2 2026, presentado el 13 ago 2026.